Patients Are Dissatisfied with Hidradenitis Suppurativa Treatment

Hidradenitis suppurativa (HS) is a chronic, inflammatory skin condition that causes painful nodules and abscesses, primarily in the armpits, groin, buttocks, and under the breasts. It is more prevalent in women, particularly Black or African American and Latinx women. HS can have a significant impact on a patient’s quality of life, leading to social isolation, challenges in intimate relationships, and mental health issues like anxiety and depression.

A recent study published in the Journal of Drugs in Dermatology aimed to evaluate patient experiences and satisfaction with current HS treatments, as well as their knowledge and perceptions of emerging FDA-approved therapies. The study revealed several critical insights that are particularly relevant for healthcare professionals treating Black patients with HS.

Key Findings and Implications for Black Patients

Disparities in Prevalence and Representation

The study acknowledged inconsistencies in the perceived prevalence of HS across different racial and ethnic groups. While the study indicated that most participants were white/Caucasian women, it is well-established that HS disproportionately affects Black or African American and Latinx women. This highlights the importance of healthcare providers being aware of these disparities and actively screening and diagnosing HS in at-risk populations.

Hidradenitis Suppurativa Underdiagnosis and Misdiagnosis

The study also found that there is often a significant delay in diagnosis, with an average of 7 to 12 years between the onset of symptoms and formal diagnosis. This delay can be particularly detrimental for Black patients, who may face additional barriers to accessing care and may experience more severe disease progression as a result.

Treatment Satisfaction and Awareness

The research revealed that a large majority of respondents were dissatisfied with their current HS treatments and unaware of FDA-approved options. This is a significant concern, as it indicates a potential gap in patient education and provider communication. For Black patients, who may already experience mistrust of the healthcare system, this lack of information can further exacerbate disparities in care.

Importance of FDA-Approved Therapies for Hidradenitis Suppurativa

The study emphasized that having access to FDA-approved therapies is crucial for improving patients’ physical and mental health, as well as their personal relationships. This is particularly important for Black patients, who may experience a greater psychosocial burden from HS due to factors such as stigma and discrimination.

Addressing Barriers to Care for Hidradenitis Suppurativa

The study identified several challenges in finding effective HS treatments, including a lack of awareness about options, an insufficient number of treatments, difficulty finding treatment for specific HS subtypes, high costs, and lack of regular access to a dermatologist or healthcare provider. These barriers can disproportionately affect Black patients, who may face socioeconomic disadvantages and limited access to quality healthcare.

Final Notes

The study’s findings highlight the urgent need for healthcare professionals to improve the management of HS, particularly in Black patients.